HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma

NCT04369937 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

HPV-Related Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma

Interventions

RADIATION: IMRT (Intensity Modulated Radiotherapy)
DRUG: Pembrolizumab
DRUG: Cisplatin
BIOLOGICAL: ISA101b

Sponsor

Dan Zandberg

Collaborators

[object Object]
[object Object]